Regeneron: Still A Biotech Juggernaut

Core Insights - Regeneron Pharmaceuticals has shown strong earnings and revenue growth in Q4 2023, driven by significant sales from its key products: Dupixent, EYLEA HD, and Libtayo [2]. Company Performance - The company reported blockbuster numbers from its leading products, which have been pivotal in its financial performance [2]. Investment Focus - The investment strategy revolves around innovative companies in the biotech sector that are developing breakthrough therapies and pharmaceuticals, with a particular interest in potential acquisition catalysts [2].